This study aimed to compare thermoplastic mask with bra in terms of setup reproducibility and immobilization of pendulous breasts during radiation therapy (RT). Forty-two female patients with breast cancer treated with either intensity modulated RT or 3-dimensional conformal RT were retrospectively reviewed. Of these, 21 benefited from thermoplastic mask immobilization and 21 used a bra. Setup accuracy was evaluated using consecutive cone beam computed tomography/electronic portal imaging device sessions over the first 3 days before treatment (systematic setting), followed by weekly cone beam computed tomography/electronic portal imaging device (random settings), and compared with the reference image to calculate the corresponding translational shift (setup error) in the 3 planes. Average absolute shift values in both systematic and random settings were compared between the 2 groups. Accuracy was analyzed by comparing the percentage of pooled settings within ±0.05 and ±0.1 cm of the reference image. Compared with a bra, use of the mask was associated with a smaller longitudinal shift in systematic settings (difference in mean: 0.27 cm; P = .027; Mann-Whitney U test) and a lesser lateral shift in random setting (difference in mean: 0.19 cm; P = .005; Mann-Whitney U test). In the pooled systematic settings, the mask performed relatively better than the bra in the lateral and longitudinal planes, with no statistical significance. In pooled random settings, mask showed greater accuracy than bra in the lateral plane with 86.0% versus 58.9% accuracy at ±0.5 cm (P < .001) and 48.8% versus 21.7% accuracy at ±0.1 cm (P < .001), respectively. There was no significant difference in the incidence of radiodermatitis between the 2 groups. However, a hypofractionation regimen was associated with a lower incidence of radiodermatitis, and the severity of skin reactions was positively correlated with treatment dose (unstandardized regression coefficient: B = .001; correlation coefficient: r = .571; P < .001). Masks provide superior reproducibility compared with commercially available bras.
4 May 2016 in Journal of Cancer Prevention & Current Research
Objectives Globally, hepatocellular Carcinoma (HCC) ranks seventh in women's cancer and fifth in men's cancer. Early identification can minimize mortality and morbidity. MicroRNAs and Toll-like receptors have been suggested as potential new biomarkers for HCC; Therefore, we explored Toll-like receptor 4 (TLR-4) and miRNA 15b-5p as new non-invasive HCC biomarkers and early detection approaches. Methodology In this case-control study, four primary groups were formed from 400 patients who participated in this study: 100 hepatitis C (HCV) patients without cirrhosis or HCC, 100 HCV with cirrhosis patients, 100 HCC and HCV patients, and 100 healthy controls. The HCC diagnosis was confirmed according to the American Association for the Study of Liver Disease (AASLD) Practice Guidelines. Triphasic computed tomography was used to assess the HCC tumor size. Real-time PCR was used to analyze miRNA 15b-5p and Toll-like receptor 4 (TLR-4) expression profiles. Results Significant diagnostic performance was achieved by miRNA 15b-5p in differentiating the HCC group from the control group, with 90 % sensitivity and 88 % specificity (AUC] 0.935, p < 0.001), while TLR-4 had moderate diagnostic performance with 85 % sensitivity and 86 % specificity (AUC:0.885, p < 0.001). Conclusions The ability of miR-15b-5p to recognize HCC was positive and it outperformed Toll-like receptor4. MiR-15b-5p has the potential to be a more precise and predictive biological marker for HCC than Toll-like receptor4. Future studies exploring different miRNAs and HCC cases from various etiologies are required to better understand the role of miRNAs in this disease and allow for more effective strategies.
1 February 2026 in Journal of Gastrointestinal Oncology
Background: Pancreatic cancer (PC) is one of the most aggressive cancers, with low survival rates. Although FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GnP) are standard first-line treatments, there is a lack of comparative real-world data from Middle Eastern populations, as well as the prognostic significance of metastatic patterns. The study aims to examine the efficacy and toxicity of FFX and GnP in advanced and metastatic PC, as well as assess how the site and number of metastases affect survival outcomes. Methods: This retrospective cohort analysis comprised 60 patients with advanced or metastatic PC treated at a tertiary center from 2019 to 2024. Patients were given either FFX (n=36) or GnP (n=24). The baseline clinicopathologic data, treatment response, toxicity, and survival outcomes were evaluated with SPSS v29. Survival was assessed using Kaplan-Meier and compared using the log-rank test. Variables with P<0.10 in univariate analysis were added to multivariable Cox regression models. Results: The demographic and clinical characteristics of patients treated with FFX and GnP were generally comparable between the two groups. In comparison to patients on GnP, those who received FFX had a slightly longer treatment duration and a substantially higher number of treatment cycles. Patients who received GnP experienced significantly more hematologic adverse events than those who received FFX. In terms of treatment response, FFX demonstrated a higher objective response rate (ORR) and disease control rate (DCR) than GnP. The metastatic site significantly influenced both overall survival (OS) and progression-free survival (PFS) survival outcomes. Kaplan-Meier curves indicate that patients with hepatic involvement experience disease progression and mortality at an earlier stage than those with nodal or other metastatic site. The number of metastatic sites did not exhibit a significant correlation with OS and PFS. In general, lung metastasis consistently demonstrated a favorable prognosis. Conclusions: In this real-world Middle Eastern group, survival outcomes were comparable between FEX and GnP. The metastatic site, particularly lung involvement, emerged as a critical prognostic predictor, implying biological heterogeneity among metastatic PC subtypes and underlining the importance of metastatic pattern in clinical prognosis.